Okami Medical has closed an oversubscribed $45 million financing round and appointed a new chief executive as the company prepares for its next phase of commercial growth and product innovation. The round was led by new investor Gilde Healthcare, with participation from existing investors including Vensana Capital and U.S. Venture Partners.
The medical technology company, based in Aliso Viejo, California, develops vascular embolization solutions and plans to use the new capital to expand its commercial presence, advance clinical programs, and continue innovating its LOBO vascular occlusion platform. The proceeds will also help support broader adoption of the company’s intuitive, versatile devices for occluding peripheral vessels.
As part of the announcement, Okami named Drew Hykes, former CEO of Inari Medical, as its new President and CEO. Bill Hoffman has been appointed Chairman of the Board. The leadership transition comes as the company aims to scale its operations and deepen its presence across a wide range of vascular anatomies.
Gilde Healthcare’s involvement also expands the company’s board, adding Geoff Pardo and Susana Amorim. Investors cited both Okami’s strong technology foundation and its significant market opportunity as key drivers behind the round.
Founded in 2017 by Inceptus Medical, Okami continues to focus on developing innovative embolization tools designed to meet the evolving needs of physicians and patients. The company’s mission is to improve outcomes for individuals with vascular disease through next-generation occlusion solutions.
KEY QUOTES:
“I’m honored to join the Okami team and have been deeply impressed by the clinical performance and versatility of the LOBO vascular occluder across a wide range of anatomies. I look forward to working with this talented team to accelerate our commercial expansion, advance our innovation pipeline, and bring this important technology to more physicians and patients.”
Drew Hykes, Chief Executive Officer of Okami Medical
“We have followed Okami for years and have been impressed by the strength of its technology and the scale of its market opportunity. We are pleased to partner with Drew again following our success at Inari and to collaborate with a highly experienced syndicate. We believe Okami’s LOBO platform has the potential to transform treatment and significantly improve outcomes for patients with serious unmet needs.”
Geoff Pardo, General Partner at Gilde Healthcare
